LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC announces that it is investigating Dynavax Technologies Corporation (“Dynavax” or the “Company”) (Nasdaq: DVAX) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired shares of Dynavax, and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you.
The investigation focuses on the U.S. Food & Drug Administration’s September 2, 2016 announcement that it cancelled Dynavax’s meeting with the Vaccines and Related Biological Products Advisory Committee on November 16, 2016, in order to allow time to review and resolve outstanding issues with the Company’s Biologics License Application for HEPLISAV-B™. When this news was announced, shares of Dynavax dropped in value.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.